Pharmaceuticals
Pharmaceutical Products and Research
Dedicated to addressing the most pressing healthcare needs in the Middle East, we work on delivering cutting-edge treatments across a broad spectrum of therapy areas that include cardiology, ophthalmology, and neurology in addition to an extensive oncology portfolio covering hematology and radiology as well. Bayer is also considered a key pharmaceutical provider for women’s health and therapies for reproductive health in the region. Today, Bayer’s Pharmaceutical Division is among the top 10 in the Middle East biopharmaceutical market.
Innovation & Technologies
Innovation at Bayer has always been powered by our people. We are committed to discovering and developing breakthrough therapies through our scientists’ expertise and strategic partners. By combining advancements in biology, chemistry, data science and artificial intelligence (AI), Bayer is at the forefront of life sciences innovation, enabling us to further boost our R&D productivity.
Guided by science and our commitment to patients, Bayer is challenging the limitations of medical treatment, ushering in a new era where science and technology constantly converge. By driving transformative innovation at every step, Bayer strives to address patients’ individual needs in order to achieve and sustain Health for all.
Collaborations & Key Initiatives
We want to partner with the best and the brightest to prevent, treat and reverse diseases and change the lives of patients through digital and health technologies.
In early 2022, Bayer signed a Memorandum of Understanding (MoU) with Syreon Research Institute and Syreon Middle East to launch the Summit and Training for Excellence in clinical Pharmacy Systems (STEPS). STEPS is an educational program that was launched in partnership with the UAE’s Ministry of Health and Prevention, with the goal of facilitating capacity building in health economics across the UAE.
In March 2022, Bayer signed Memorandum of Understanding (MoU) with the Egyptian Ministry of Health and Population (MOHP) to provide new treatment options for patients diagnosed with Hepatocellular Carcinoma (HCC). Given the disease’s high prevalence in the country, both entities are committed to improving healthcare services provided for HCC where Bayer has also pledged, as part of an HCC sustainability capacity-building project, to partner with MOHP and enhance healthcare professionals’ capabilities in early diagnosis for patients living with HCC.
In addition on November 2024, Bayer signed a MoU with the Egyptian MOHP, under the patronage of H.E. Mr. Abdel Fattah El-Sisi, President of Egypt, the Ministry of Health and Population, and in the presence of H.E. Dr. Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population, to support presidential efforts to promote early diagnosis and treatment of prostate cancer in Egypt.
Bayer Middle East has launched a five-year partnership with United Nation Population Fund (UNFPA) Egypt to support the Ministry of Health and Population “Your Right to Plan” campaign, aiming to improve family planning and reproductive health services for underserved communities across Egypt. The collaboration, marked by a EUR 330,000 donation, seeks to raise awareness, provide essential medical services, and increase access to family planning resources. This initiative aligns with Bayer’s commitment to sustainable development and its goal of enhancing health outcomes for millions of women.